Tata Chemicals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
TATACHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tata Chemicals' Board approved the unaudited consolidated and audited standalone financial results for Q2 and H1 FY26 (ended September 30, 2025). Consolidated revenue from operations fell to ₹3,877 crore in Q2 from ₹3,999 crore a year ago, a decline of about 3%. Profit before tax dropped sharply to ₹181 crore (vs ₹304 crore) due to a ₹65 crore exceptional charge linked to additional closure costs at the UK Lostock soda ash plant, and softer basic chemistry performance. Net profit from continuing operations for the quarter fell to ₹154 crore from ₹267 crore. However, H1 FY26 PAT rose modestly to ₹470 crore from ₹457 crore. Operating margin compressed to 6.50% from 8.53% YoY. Separately, the Board approved raising up to ₹1,500 crore through non-convertible debentures (NCDs) on a private placement basis. Auditors B S R & Co. LLP issued an unmodified opinion on standalone results and an unmodified review conclusion on the consolidated numbers.
Weak Q2 print with sharp profit decline and margin compression may pressure the stock in the short term, though H1 numbers are marginally better. The ₹1,500 crore NCD issuance will increase debt (debt-equity already up to 0.32x from 0.28x) but signals available liquidity headroom for capex and growth investments.